APA (7th ed.) Citation

YN, L., SY, J., LS, Z., XJ, T., Z, M., Y, S., & JY, L. (2026). Paeoniflorin as a candidate disease-modifying therapy for diabetic peripheral neuropathy: Mechanisms, exposure challenges, and translational priorities. Frontiers in pharmacology, 17, 1751578. https://doi.org/10.3389/fphar.2026.1751578

Chicago Style (17th ed.) Citation

YN, Liu, Jia SY, Zhou LS, Tang XJ, Ming Z, Su Y, and Lin JY. "Paeoniflorin as a Candidate Disease-modifying Therapy for Diabetic Peripheral Neuropathy: Mechanisms, Exposure Challenges, and Translational Priorities." Frontiers in Pharmacology 17 (2026): 1751578. https://doi.org/10.3389/fphar.2026.1751578.

MLA (9th ed.) Citation

YN, Liu, et al. "Paeoniflorin as a Candidate Disease-modifying Therapy for Diabetic Peripheral Neuropathy: Mechanisms, Exposure Challenges, and Translational Priorities." Frontiers in Pharmacology, vol. 17, 2026, p. 1751578, https://doi.org/10.3389/fphar.2026.1751578.